Photo Gallery



News & Updation

  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  • WJPPS Impact Factor
  • Its our Pleasure to Inform you that WJPPS Impact Factor has been increased from  7.454 to 7.632  due to high quality Publication at International Level

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • SEPTEMBER 2021 Issue has been successfully launched on 1 September 2021.



Harsiddhi M. Chaudhary*, Kisan R. Jadhav and Vilasrao J. Kadam


A new and improved generation of lipid nanoparticles named as Nanostructured lipid carriers (NLCs) has been developed to overcome the limitations of traditional lipid nanoparticles. NLCs are designed by controlled mixing of solid lipids with spatially incompatible liquid lipids leading to special nanostructures with improved drug loading, drug release profile and stability. The purpose of present study was to develop and evaluate NLCs based oral formulation of Glipizide. Glipizide, an oral hypoglycemic agent which is most commonly used in the treatment of noninsulin dependent diabetes mellitus. It has poor solubility in water and the half life of drug is 2-4 h. Hence by formulating Glipizide loaded NLCs (GPZ-NLCs) the dosing frequency will be decreased and also absorption variations will be eliminated. GPZ-NLCs were prepared by high shear homogenization coupled with ultrasonication method. Entrapment efficiency and mean particle size of GPZ-NLCs dispersion was found to be 86.73% and 99.83 nm respectively. Free flowing GPZ-NLCs powder was produced from dispersion after lyophilization using trehalose as a cryoprotectant, which was then used to develop GPZ-NLCs based capsule. In vitro drug release of GPZ-NLCs based capsule was found to be 86.79% with initial burst release followed by sustained release as compared marketed SR tablet which showed a slow and sustained release of 78.72% at the end of 24 hrs. Based on these results, it is concluded that the GPZ-NLCs based capsule may be proposed as sustained release formulation for oral delivery of Glipizide.

Keywords: Glipizide; Nanostructured lipid carriers; Noninsulin dependent diabetes mellitus; Sustained release; Oral delivery.

[Full Text Article]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More